Fortress Biotech shares surge 20.34% intraday as Cyprium Therapeutics sells rare pediatric disease priority review voucher for $205M in cash, boosting cash reserves and liquidity.

Fortress Biotech surged 20.34% intraday, driven by its subsidiary Cyprium Therapeutics' agreement to sell a rare pediatric disease priority review voucher for $205 million in cash, set to close on February 22, 2026. The transaction is expected to significantly bolster Fortress's cash reserves and liquidity, with the company holding an 80.4% stake in Cyprium and projected to receive at least $100 million in proceeds to fund core biopharma development and debt repayment. Cyprium will retain royalty rights on ZYCUBO's net sales for Menkes disease and up to $129 million in milestone payments, enhancing long-term revenue potential.